Aruni Ghose, Director and Chief Executive Officer at Canprecise AI, Chief Medical Officer at Shiksak, shared a post on LinkedIn:
“The Beginning of a Cancer Inequalities Treatment Response Real World Evidence Revolution
All eyes on the 4 Posters at ESMO – European Society for Medical Oncology Breast Cancer 2026.
Ethnicity Based Cancer Drug Benchmarking and Ethnicity Stratified Oncology Treatment Endpoints are non existent in Clinical Trial Reporting, let alone Multicentre Real World Literature – Sitting at the Velindre Cancer Service Velindre University NHS Trust I was proud to have introduced this Novel Benchmarking Concept to Identify Variations in Treatment Response from Drugs of the Same Class using Country specific Evidence with Dominant (>85%) Ethnicities. The quest was to further streamline and inform Clinical Practice.
The Birth of the Virtual Cancer Inequalities Lab founded by Disha Khanna, Joecelyn Kirani T., Olivia B. executed this in the Metastatic HR+ HER2- Breast Cancer Setting amongst the 3 CDK4/6 inhibitors – Palbociclib, Ribociclib, Abemaciclib
This would not have been possible without our wonderful team – Isabella Koprivec, Vahe Grigoryan, Mariam Khachatryan, Ishikaa Mukherjee, Vriddhi Urs, Adan Khan, Aaron Benedict, Alma Jbeili, Patricia Lapitan and my Seniors on a Mission towards GlobalOncology change – Dr Olubukola Ayodele, Akash Maniam, Sarah Adomah, Dr Yetunde Owoseni
Inspired by Cancer Health Disparities – London Global Cancer Week (LGCW), UKI Global Cancer Network, OncoDaily Breast, Make 2nds Count, Future Dreams Breast Cancer Charity, CoppaFeel!”
Other Articles Featuring Aruni Ghose On OncoDaily.
